News
WHY IT'S IMPORTANT. Cycle Pharma's $8 per share proposal is an 80% premium to Vanda's last closing price, valuing the company at $488 million. The potential offer follows a 4.5% fall in Vanda's ...
In all, I maintain my buy recommendation on Vanda Pharmaceuticals with the 4.8/5 stars rating On a two years horizon, I expect the $50.24 price target to be reached.
Vanda Pharmaceuticals has seen an increase in net product sales this year — in a landscape the Covid-19 pandemic has generally challenged and after a rocky period for the D.C. biotech.
Shares of Vanda Pharmaceuticals (VNDA 1.77%) fell more than 19% today after the company announced it was pursuing legal action against the U.S. Food and Drug Administration.
Vanda Pharmaceuticals Inc. VNDA shares are trading lower after Future Pak withdrew its proposal to purchase the company. “Consistent with the position indicated in its June 13, 2024 letter to ...
Vanda acquired rights to U.S. and Canadian rights to PONVORY ® from Actelion Pharmaceuticals Ltd., a Johnson& Johnson Company. PONVORY ® is approved by the U.S. Food and Drug Administration and ...
HC Wainwright sets an $18 target on Vanda Pharmaceuticals amid a 30% discount to cash reserves. Vanda's portfolio could reach key clinical and regulatory milestones within 6–18 months.
Vanda Pharmaceuticals (NASDAQ: VNDA) looks to be a fundamentally strong, early-stage biotech investment opportunity based on my analysis, which is currently trading at a 42% discount to its early ...
Vanda Pharmaceuticals is advancing clinical trials for several new drugs that, if approved, would mean new revenue streams for the D.C. company.
What happened Shares of Vanda Pharmaceuticals (NASDAQ: VNDA) fell more than 19% today after the company announced it was pursuing legal action against the U.S. Food and Drug Administration.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results